Dr. Rick Turner, Chairman of the Department of Clinical Research at the Campbell University School of Pharmacy, has been invited to participate in the Cardiac Safety Research Consortium, a national organization sponsored by the Food and Drug Administration (FDA), Duke University Clinical Research Institute (DCRI), and numerous pharmaceutical companies. The purpose of the Consortium is to bring together experts from government, academia, and pharmaceutical sponsors to address cardiac safety, one of the most important topics in contemporary drug development and drug therapy. The intent of this collaboration is to develop evaluative tools, standards, validated tests, and cardiovascular biomarkers related to broad aspects of cardiac safety, including arrhythmia, thrombosis, myocardial infarction, and heart failure.One of Dr. Turner’s initial responsibilities will likely be to work collaboratively with other Consortium members to write “Points to Consider” documents. These documents are intended to facilitate discussions between all stakeholders that will benefit drug development research nationally and internationally, thereby enhancing the efficient development of safe and effective drugs and bringing new treatments to patients as soon as possible. The Campbell University School of Pharmacy is pleased that its faculty can contribute to patient safety in this manner.
Campbell professor to participate in drug safety consortium